SG11201905601VA - Scn9a antisense pain killer - Google Patents
Scn9a antisense pain killerInfo
- Publication number
- SG11201905601VA SG11201905601VA SG11201905601VA SG11201905601VA SG11201905601VA SG 11201905601V A SG11201905601V A SG 11201905601VA SG 11201905601V A SG11201905601V A SG 11201905601VA SG 11201905601V A SG11201905601V A SG 11201905601VA SG 11201905601V A SG11201905601V A SG 11201905601VA
- Authority
- SG
- Singapore
- Prior art keywords
- gyeonggi
- yongin
- gil
- giheung
- apt
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract 3
- 230000036407 pain Effects 0.000 title abstract 3
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 101150080511 Scn9a gene Proteins 0.000 title 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 4
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 3
- 108091093037 Peptide nucleic acid Proteins 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract 1
- 108020005067 RNA Splice Sites Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000048004 human SCN9A Human genes 0.000 abstract 1
- 229960004194 lidocaine Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 abstract 1
- 229950010357 tetrodotoxin Drugs 0.000 abstract 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) WI P0 I PCT omit VIII °nolo oil! iflo oimIE (10) International Publication Number WO 2018/138585 Al (51) International Patent Classification: C07K 14/00 (2006.01) C12N 15/113 (2010.01) (21) International Application Number: PCT/IB2018/000160 (22) International Filing Date: 23 January 2018 (23.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/449,738 24 January 2017 (24.01.2017) US (71) Applicant: OLIPASS CORPORATION [KR/KR]; 20th Floor, Ace Dongbaek Tower, 16 Beon-gil, 16-4 Dongbaek Jungang-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17105 (KR). (72) Inventors: CHUNG, Shin; Apt. 103-3703, 527 Beon- gil 80, 527 Beon-gil 80, Dongbaek Jukjeondae-ro, Gi- heung-gu, Yongin-si, Gyeonggi-do 16990 (KR). JUNG, Daram; The Sharp Central-city 1406-1502, 19 Dongtan- daerosibeom-gil, Hwaseong-si, Gyeonggi-do (KR). CHO, Bongjun; 316-1102 Ssangyong Apt. 20, Jungbudae-ro, 788 Beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 17077 (KR). JANG, Kangwon; Apt. 1701-1702, Dongbaek8-ro 9, Giheung-gu, Yongin-si, Gyeonggi-do 16998 (KR). JEON, Hyun Ju; 105 Dong 1301 Ho, 62-28, Eojeong-ro, Gihe- ung-gu, Yongin-si, Gyeonggi-do (KR). BAE, Jinyoung; 3rd Floor 302, Pyeongchonl-ro 8beon-gil 5-19, Gihe- ung-gu, Yongin-si, Gyeonggi-do (KR). BAE, Taeyeon; 201 Ho, 31, Pyeongchon 3-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17001 (KR). JEON, Yeasel; 506, Hou-star, 98-32, Dongbaekjukjeon-daero, 527 Beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do (KR). LEE, Jun Yeon; Apt. #201-706, 33, Yeonwon-ro 42beon-gil, Giheung-gu, Yon- gin-si, Gyeonggi-do (KR). PARK, Sun Hwa; 717-701 SK View Apt. 27-7, Baegot 3-ro, Siheung-si, Gyeonggi-do (KR). AN, Dan Bi; Apt. # C-608, 283, Dongbaekjun- gang-ro, Giheung-gu, Yongin-si, Gyeonggi-do (KR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — (54) Title: SCN9A ANTISENSE PAIN KILLER Figure lA HO OH Lidocaine Tetrodotoxin el (57) : The current invention provides peptide nucleic acid derivatives targeting the 3' splice site of exon 4 in the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce SCN9A mRNA splice variant(s) lacking the SCN9A exon 4 in cells, and are useful to safely treat pains or conditions involving Na v 1.7 activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762449738P | 2017-01-24 | 2017-01-24 | |
PCT/IB2018/000160 WO2018138585A1 (en) | 2017-01-24 | 2018-01-23 | Scn9a antisense pain killer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201905601VA true SG11201905601VA (en) | 2019-08-27 |
Family
ID=62979263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201905601VA SG11201905601VA (en) | 2017-01-24 | 2018-01-23 | Scn9a antisense pain killer |
Country Status (14)
Country | Link |
---|---|
US (1) | US11162104B2 (en) |
EP (1) | EP3573998A4 (en) |
JP (1) | JP7241019B2 (en) |
KR (1) | KR102592876B1 (en) |
CN (1) | CN110536895B (en) |
AU (1) | AU2018213153B2 (en) |
BR (1) | BR112019014689A2 (en) |
CA (1) | CA3051178A1 (en) |
IL (1) | IL267881B2 (en) |
MX (1) | MX2019008445A (en) |
RU (1) | RU2762293C2 (en) |
SG (1) | SG11201905601VA (en) |
WO (1) | WO2018138585A1 (en) |
ZA (1) | ZA201905064B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018122610A1 (en) * | 2016-12-30 | 2018-07-05 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
KR102304280B1 (en) | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | Acetyl-CoA Carboxylase2 Antisense Oligonucleotides |
WO2021247995A2 (en) * | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
WO2022147541A1 (en) * | 2021-01-04 | 2022-07-07 | Exicure Operating Company | Compounds for modulating scn9a expression |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617422B1 (en) * | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
US9278088B2 (en) | 2002-02-19 | 2016-03-08 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
US7060723B2 (en) * | 2003-08-29 | 2006-06-13 | Allergan, Inc. | Treating neurological disorders using selective antagonists of persistent sodium current |
WO2007109324A2 (en) | 2006-03-21 | 2007-09-27 | Xenon Pharmaceuticals, Inc. | Potent and selective nav 1.7 sodium channel blockers |
CN101605835B (en) * | 2006-10-20 | 2013-11-20 | 自然工作有限责任公司 | Impact modified polylactide resins |
US8183221B2 (en) | 2007-09-05 | 2012-05-22 | Medtronic, Inc. | Suppression of SCN9A gene expression and/or function for the treatment of pain |
CN101480393A (en) * | 2008-01-07 | 2009-07-15 | 云南昊邦制药有限公司 | Application of bulleyaconitine A in preparing medicament for treating Nav1.7 ache disease |
JP5143031B2 (en) | 2008-01-22 | 2013-02-13 | パナソニック株式会社 | Optical disc drive, optical disc system, moving body equipped with optical disc system, program, and recording medium |
KR20090098710A (en) * | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | Peptide nucleic acid derivatives with good cell penetration and affinity for nucleic acid |
WO2009143277A2 (en) * | 2008-05-20 | 2009-11-26 | Intradigm Corporation | Compositions comprising hscn9a sirna and methods of use thereof |
KR20110087436A (en) | 2010-01-26 | 2011-08-03 | 주식회사 씨티아이바이오 | Scn9a antisense oligonucleotide |
PT2585596T (en) * | 2010-06-23 | 2021-03-23 | Curna Inc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
CA2830065A1 (en) * | 2011-03-16 | 2012-09-20 | Amgen Inc. | Potent and selective inhibitors of nav1.3 and nav1.7 |
TWI642438B (en) * | 2011-06-24 | 2018-12-01 | 可娜公司 | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
KR102427575B1 (en) * | 2016-08-08 | 2022-08-01 | 올리패스 주식회사 | Androgen receptor antisense oligonucleotides |
US20190218255A1 (en) | 2016-09-16 | 2019-07-18 | Olipass Corporation | Scn9a antisense oligonucleotides |
WO2018122610A1 (en) | 2016-12-30 | 2018-07-05 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
-
2018
- 2018-01-23 CA CA3051178A patent/CA3051178A1/en active Pending
- 2018-01-23 EP EP18744379.1A patent/EP3573998A4/en active Pending
- 2018-01-23 BR BR112019014689-0A patent/BR112019014689A2/en unknown
- 2018-01-23 JP JP2019539749A patent/JP7241019B2/en active Active
- 2018-01-23 KR KR1020197023676A patent/KR102592876B1/en active IP Right Grant
- 2018-01-23 WO PCT/IB2018/000160 patent/WO2018138585A1/en unknown
- 2018-01-23 AU AU2018213153A patent/AU2018213153B2/en active Active
- 2018-01-23 US US16/480,147 patent/US11162104B2/en active Active
- 2018-01-23 SG SG11201905601VA patent/SG11201905601VA/en unknown
- 2018-01-23 MX MX2019008445A patent/MX2019008445A/en unknown
- 2018-01-23 CN CN201880018551.7A patent/CN110536895B/en active Active
- 2018-01-23 IL IL267881A patent/IL267881B2/en unknown
- 2018-01-23 RU RU2019125286A patent/RU2762293C2/en active
-
2019
- 2019-07-31 ZA ZA2019/05064A patent/ZA201905064B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US11162104B2 (en) | 2021-11-02 |
BR112019014689A2 (en) | 2020-02-18 |
IL267881B2 (en) | 2024-03-01 |
JP7241019B2 (en) | 2023-03-16 |
RU2019125286A3 (en) | 2021-05-14 |
CA3051178A1 (en) | 2018-08-02 |
KR102592876B1 (en) | 2023-10-23 |
RU2019125286A (en) | 2021-02-26 |
ZA201905064B (en) | 2022-10-26 |
CN110536895A (en) | 2019-12-03 |
AU2018213153A1 (en) | 2019-08-15 |
KR20190103372A (en) | 2019-09-04 |
EP3573998A1 (en) | 2019-12-04 |
CN110536895B (en) | 2023-10-20 |
RU2762293C2 (en) | 2021-12-17 |
US20190338292A1 (en) | 2019-11-07 |
EP3573998A4 (en) | 2020-12-16 |
JP2020506686A (en) | 2020-03-05 |
IL267881B1 (en) | 2023-11-01 |
IL267881A (en) | 2019-09-26 |
WO2018138585A1 (en) | 2018-08-02 |
MX2019008445A (en) | 2020-02-10 |
AU2018213153B2 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201905601VA (en) | Scn9a antisense pain killer | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201806340YA (en) | Zika virus vaccine | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201908547VA (en) | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804836RA (en) | Treatment of fibrosis | |
SG11201408307VA (en) | Needle guard | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201908060PA (en) | Wound healing medicament | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201407961WA (en) | Risperidone or paliperidone implant formulation | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201808964PA (en) | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |